Dr. Emmanuel Nicholas Soultanakis, MD

Dr. Soultanakis practices at Alfond Center for Health in Augusta, Maine.

Dr. Soultanakis' NPI, 1659489284, was assigned on August 25, 2006. Dr. Soultanakis graduated from University of Vermont College of Medicine in 1996. Dr. Soultanakis holds Maine license MD19505.

Dr. Soultanakis' primary practice is Alfond Center for Health, at 35 Medical Center Pkwy, Augusta, ME 04330 in Kennebec County. The practice phone is (207) 873-9841.

Dr. Soultanakis' primary practice is Alfond Center for Health in Augusta, Maine. Dr. Soultanakis is also affiliated with MaineHealth Maine Medical Center. The medical group on file is Saint Luke's Medical Group. Dmand AI also links Dr. Soultanakis to 3 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Soultanakis practices, 5 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Soultanakis' primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dmand AI has Dr. Soultanakis' licenses on file in 3 states: Maine, Missouri and Vermont.

CMS data shows 172 Medicare services from Dr. Soultanakis across 4 procedure codes in 2024, for 101 Medicare patients. Medicare paid $21,434 for them.

CMS counts 101 Medicare patients who saw Dr. Soultanakis in 2024. The largest group is 65 to 74, with 52 patients. 69% of them have high blood pressure, and 68% have high cholesterol. 31% are also on Medicaid. Their average risk score is 1.43, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Soultanakis' median patient age at 69, with 99% women.

In 2024, Dr. Soultanakis wrote 125 Medicare Part D claims for 40 patients. 98% of them were for generic drugs. CMS names the drug for 93 of them, across 4 drugs with 11 or more claims each, at $1,220 in total drug cost. In 2023, CMS named 82 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Soultanakis for performance year 2024, reported through an alternative payment model (APM). Dr. Soultanakis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Soultanakis as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

CMS Open Payments shows 13 general payments to Dr. Soultanakis from 3 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 74% of the total. Intuitive Surgical, Inc. paid the most, $1,412.

Dr. Soultanakis graduated from University of Vermont College of Medicine in 1996.